Probióticos en el síndrome de intestino irritable con predominio de diarrea / Probiotics for the treatment of diarrhea predominant irritable bowel syndrome

Una mujer de 36 años, diagnosticada con síndrome de intestino irritable a predominio de diarrea (SII-D) acude a la consulta médica. Ella pregunta si el uso de probióticos sería útil para controlar los episodios de diarrea, ya que los fármacos con los que está siendo tratada no le resultan eficaces. Se realizó una búsqueda bibliográfica con el objetivo de en contrar evidencia en respuesta a su consulta, tras la cual se seleccionaron dos ensayos clínicos y una revisión sistemática. Se evidenciaron diversos resultados en cuanto al uso de probióticos en el SII-D y se discutieron los riesgos y beneficios del tratamiento, así como las implicancias en la vida de la paciente. (AU)

A 36-year-old woman diagnosed with diarrhea predominant irritable bowel syndrome (D-IBS) goes to meet the doctor. She raises whether the use of probiotics would be useful for controlling diarrhea episodes, since the drugs which she is being treated with, are not effective. A bibliographic search was conducted with the objective of finding evidence in response toher query. Two clinical trials and a systematic review were found. Variable results were found regarding the use of probioticsin D-IBS. The risks and benefits of the treatment were discussed, as well as the implications in the patient's lifestyle. (AU)

Avaliação do consumo alimentar de pacientes com síndrome do intestino irritável em acompanhamento ambulatorial / Evaluation of carbohydrate and fiber consumption in patients with irritable bowel syndrome in outpatient treatment

ABSTRACT BACKGROUND: Irritable bowel syndrome (IBS) is a chronic functional condition, which main symptoms of pain, discomfort and abdominal distension, constipation, diarrhea, altered fecal consistency and sensation of incomplete evacuation can be influenced by the presence of dietary fiber and fermentable carbohydrates (FODMAPs). This study aimed to assess the relationship between the quantity of fermentable carbohydrates (FODMAP) and fiber consumed by individuals diagnosed with IBS, and their classification according to the Rome III criteria. METHODS: A transversal study was carried out in the Intestinal Outpatient Clinic of the Gastroenterology Discipline of UNIFESP. The nutrients of interest for the study were: fiber, general carbohydrates and FODMAPs, with intake quantity measured in grams, analyzed through portions consumed. A nutrition log was used, along with a semi-quantitative questionnaire of consumption frequency. RESULTS: The sample included 63 adult patients; 21 with constipated IBS, 21 with diarrhea IBS, and 21 with mixed IBS. Carbohydrate intake was suboptimal in 55.6% of patients in all groups; excessive consumption was identified in 38.1% of the diarrhea group, 14.3% of the mixed group and 38.1% of the constipated group. Low consumption of carbohydrates was found in 28.6% of diarrhea patients and 47.6% of the mixed group. A mean intake of 23 g of fiber per day was identified, lower than recommended. CONCLUSION: The study identified a number of inadequacies in the consumption of different nutrients, excessive carbohydrate intake, especially FODMAPs, identified by the respondents as responsible for a worsening of their conditions. By contrast, other food groups such as meat, eggs and dairy were consumed by the sample population in insufficient quantities.

RESUMO CONTEXTO: A síndrome do intestino irritável é um distúrbio funcional crônico, no qual a dieta, principalmente o teor de fibra dietética e presença de carboidratos fermentativos (FODMAPs) podem influenciar nos principais sintomas: dores, desconforto e/ou distensão abdominal, constipação, diarreia, alteração na consistência das fezes, sensação de evacuação incompleta. OBJETIVO: Este estudo teve como objetivo avaliar as quantidades de carboidratos fermentativos (FODMAP) e fibras consumidas por indivíduos com o diagnóstico de síndrome do intestino irritável e relacionar com seu modelo da classificação, segundo os critérios Roma III. MÉTODOS: Estudo transversal, realizado no Ambulatório de Doenças Intestinais da Disciplina de Gastroenterologia/UNIFESP. Os nutrientes de interesse para o estudo foram: fibras, carboidratos em geral e FODMAPs, calculando-se suas quantidades em gramas, analisadas através das porções consumidas. Os instrumentos de pesquisa utilizados: ficha de acompanhamento nutricional e questionário de frequência alimentar semi-quantitativo. RESULTADOS: A amostra incluiu 63 pacientes adultos, com síndrome do intestino irritável constipado (21), diarreico (21) e misto (21). O consumo de carboidratos mostrou-se inadequado em 55,6% dos indivíduos em todos os grupos; os que tinham alto consumo (38,1%) pertenciam ao grupo diarreia, 14,3% ao misto e 38,1 % ao constipado. Baixo consumo deste nutriente foi 28,6% nos casos de diarreia e 47,6% do misto. Observamos uma ingestão média de fibras equivalente à 23 g/dia, nos três grupos, inferior ao recomendado. CONCLUSÃO: O estudo permitiu reconhecer várias inadequações no consumo dos diferentes grupos de alimentos, particularmente excesso de carboidratos, incluindo os classificados como FODMAPs, identificados pelos doentes como responsáveis pela piora das suas queixas. Em contrapartida, nutrientes fundamentais, como carnes, ovos, leite e derivados estiveram referidos em níveis abaixo do recomendado.

Patologías funcionales post-infecciosas: epidemiología, factores de riesgo y tratamiento / Post-infectious functional gastrointestinal disorders: epidemiology, risk factors and treatment

Infectious gastroenteritis is a risk factor for developing post-infectious functional gastrointestinal disorders (PI-FGDs), mainly irritable bowel syndrome (IBS) and functional dyspepsia (FD). It is a significant subgroup of patients due to frequent episodes of gastrointestinal infections. Symptoms in PI-FGD patients can prevail for more than twelve months, especially if infective agents are bacteria or parasites. Symptoms are indistinguishable from their non-infective equivalents (IBS and FD). Risk factors for developing PI-FGD are: female gender, type and severity of the gastrointestinal infection, high anxiety levels and younger age. Main pathogenic mechanisms are alteration of permeability and immunity. Mucosa inflammation prevails only at early stage; however, with follow-up it can be reduced or normalized. Nevertheless, certain alterations prevail, such as hypersensitivity. These events are treated in the same way as IBS or FD.

La gastroenteritis infecciosa es un factor de riesgo para desarrollar un trastorno digestivo funcional postinfeccioso (TDF-PI), principalmente síndrome de intestino irritable (SII) y dispepsia funcional (DF). Es un subgrupo de pacientes relevante debido a lo frecuente que son las infecciones gastrointestinales. Los síntomas en los pacientes con TDF-PI se pueden prolongar por más de un año, especialmente cuando los agentes infecciosos son bacterias o parásitos. Los síntomas son indistinguibles con respecto a los de sus equivalentes no infecciosos (SII y DF). Los factores de riesgo para desarrollar TDF-PI son el sexo femenino, el tipo y la severidad de la infección gastrointestinal, los niveles altos de ansiedad, y la menor edad. Los principales mecanismos patogénicos son la alteración de la permeabilidad y de inmunidad. La inflamación de la mucosa predomina solo al principio pero con el seguimiento esta disminuye o se normaliza, a pesar de lo cual ciertas alteraciones como la hiperensibilidad permanecen. Estos cuadros se tratan de la misma manera que un SII o DF.

Association between Diet and Lifestyle Habits and Irritable Bowel Syndrome: A Case-Control Study

BACKGROUND/AIMS: Recent papers have highlighted the role of diet and lifestyle habits in irritable bowel syndrome (IBS), but very few population-based studies have evaluated this association in developing countries. The aim of this study was to evaluate the association between diet and lifestyle habits and IBS. METHODS: A food frequency and lifestyle habits questionnaire was used to record the diet and lifestyle habits of 78 IBS subjects and 79 healthy subjects. Cross-tabulation analysis and logistic regression were used to reveal any association among lifestyle habits, eating habits, food consumption frequency, and other associated conditions. RESULTS: The results from logistic regression analysis indicated that IBS was associated with irregular eating (odds ratio [OR], 3.257), physical inactivity (OR, 3.588), and good quality sleep (OR, 0.132). IBS subjects ate fruit (OR, 3.082) vegetables (OR, 3.778), and legumes (OR, 2.111) and drank tea (OR, 2.221) significantly more frequently than the control subjects. After adjusting for age and sex, irregular eating (OR, 3.963), physical inactivity (OR, 6.297), eating vegetables (OR, 7.904), legumes (OR, 2.674), drinking tea (OR, 3.421) and good quality sleep (OR, 0.054) were independent predictors of IBS. CONCLUSIONS: This study reveals a possible association between diet and lifestyle habits and IBS.

Diarreia funcional e síndrome do intestino irritável em crianças / Functional diarrea and the irritable bowel syndrome in childhood

A autora atualiza, de forma prática, os conhecimentos modernos sobre duas patologias frequentes na infância, a diarreia funcional e a síndrome do intestino irritável.O trabalho revê o histórico e a sinonímia das mesmas, trata de sua etiopatogenia, aspectos clínicos e diagnóstico, diagnóstico diferencial e tratamento.No capítulo referente à terapêutica apresenta a conduta atual, tanto dietética como medicamentosa, ressaltando as controvérsias ainda existentes a respeito.

Treatment of postinfectious irritable bowel syndrome and noninfective irritable bowel syndrome with mesalazine / Tratamento da síndrome do intestino irritável pós-infecciosa e da síndrome do intestino irritável não-infecciosa com mesalazina

CONTEXT: Recent studies support the hypothesis that postinfectious irritable bowel syndrome and some irritable bowel syndrome patients display persistent signs of minor mucosal inflammation. Mesalazine has intestinal anti-inflammatory properties including cyclooxygenase and prostaglandin inhibition. The effects of mesalazine on postinfectious irritable bowel syndrome and noninfective irritable bowel syndrome patients are still unknown. OBJECTIVE: To observe the effects of mesalazine on postinfectious irritable bowel syndrome and noninfective irritable bowel syndrome with diarrhea patients. METHODS: Based on Rome III criteria, 61 irritable bowel syndrome with diarrhea patients (18 years old or more) were included in the evaluation. Patients were divided into two groups: postinfectious irritable bowel syndrome group, with 18 patients medicated with mesalazine 800 mg 3 times a day for 30 days; noninfective irritable bowel syndrome group, with 43 patients medicated with mesalazine 800 mg 3 times a day for 30 days. Symptom evaluations at baseline and after treatment were performed by means of a four-point Likert scale including stool frequency, stool form and consistency (Bristol Stool Scale), abdominal pain and distension (maximum score: 16; minimum score: 4). RESULTS: Postinfectious irritable bowel syndrome group presented a statistically significant reduction of the total symptom score (P<0.0001). The stool frequency was significantly reduced (P<0.0001), and stool consistency, improved (P<0.0001). Abdominal pain (P<0.0001) and abdominal distension were significantly reduced (P<0.0001). Noninfective irritable bowel syndrome group presented a statistically significant reduction of total symptom score (P<0.0001). Also, the stool frequency was significantly reduced (P<0.0001) and stool consistency, improved (P<0.0001). Abdominal pain (P<0.0001) and abdominal distention were significantly reduced (P<0.0001). There was no statistical difference between postinfectious irritable bowel syndrome group and noninfective irritable bowel syndrome group on total symptom score results at 30th day of therapy with mesalazine 800 mg 3 times a day. (P = 0.13). CONCLUSION: Mesalazine reduced key symptoms of postinfectious irritable bowel syndrome and noninfective irritable bowel syndrome with diarrhea patients.

CONTEXTO: Estudos recentes sustentam a hipótese que a síndrome do intestino irritável pós-infecciosa e alguns pacientes com síndrome do intestino irritável mostram sinais menores de inflamação persistente da mucosa. A mesalazina tem propriedades anti-inflamatórias intestinais, incluindo a inibição da ciclooxigenase e das prostaglandinas. Os efeitos da mesalazina na síndrome do intestino irritável pós-infecciosa e em pacientes com síndrome do intestino irritável não-infecciosa ainda são desconhecidos. OBJETIVO- Observar os efeitos da mesalazina em pacientes com síndrome do intestino irritável pós-infecciosa e síndrome do intestino irritável com diarréia não-infecciosa. MÉTODOS: Com base nos critérios de Roma III, 61 pacientes síndrome do intestino irritável acompanhado de diarréia (18 anos ou mais de idade) foram incluídos na avaliação. Os pacientes foram divididos em dois grupos: grupo síndrome do intestino irritável pós-infecciosa, com 18 pacientes medicados com mesalazina 800 mg 3 vezes ao dia por 30 dias; grupo síndrome do intestino irritável não-infecciosa, com 43 pacientes medicados com mesalazina 800 mg 3 vezes ao dia por 30 dias. Avaliações dos sintomas no início e após o tratamento foram realizadas por meio de uma escala Likert de 4 pontos, incluindo a frequência das evacuações, forma e consistência das fezes (Bristol Stool Scale), dor e distensão abdominal (pontuação máxima: 16; pontuação mínima: 4). RESULTADOS: O grupo síndrome do intestino irritável pós-infecciosa apresentou redução estatisticamente significante do escore total de sintomas (P<0,0001). A frequência de evacuações foi significativamente reduzida (P<0,0001) e a consistência das fezes melhoraram (P<0,0001). Dor abdominal (P<0,0001) e distensão abdominal foram significativamente reduzidas (P<0,0001). O grupo síndrome do intestino irritável não-infecciosa apresentou redução estatisticamente significante do escore total de sintomas (P<0,0001). Além disso, a frequência de fezes foi significativamente reduzida (P<0,0001) e a consistência das fezes melhoraram (P<0,0001). Dor abdominal (P<0,0001) e distensão abdominal foram significativamente reduzidas (P<0,0001). Não houve diferença estatística entre o grupo síndrome do intestino irritável pós-infecciosa e o grupo síndrome do intestino irritável não-infecciosa sobre os resultados da pontuação total dos sintomas em 30 dias de terapia com mesalazina 800 mg 3 vezes ao dia (P= 0,13). CONCLUSÃO: O uso de mesalazina reduziu os principais sintomas da síndrome do intestino irritável pós-infecciosa e da síndrome do intestino irritável com diarréia não-infecciosa.

Influência da resposta individual ao estresse e das comorbidades psiquiátricas na síndrome do intestino irritável: [revisão] / Influence of individual response to stress and psychiatric comorbidity in irritable bowel syndrome: [review]

CONTEXTO: A síndrome do intestino irritável (SII) é um distúrbio clínico comum, porém ainda pouco compreendida, uma vez que o desenvolvimento dos seus sintomas está fortemente relacionado ao estresse, ansiedade e depressão. OBJETIVOS: Revisar a literatura a fim de verificar se, de fato, existe influência do estresse e das comorbidades psiquiátricas no desenvolvimento, diagnóstico e tratamento para os portadores da SII. MÉTODOS: A revisão foi realizada por meio de pesquisa na base de dados MedLine e Lilacs entre 1990 e 2009, usando-se as palavras-chave "estresse", "comportamento", "psiquiatria" e "síndrome do intestino irritável". RESULTADOS: Foram selecionados 38 artigos que relacionaram a síndrome do intestino irritável à reação individual ao estresse e comorbidade psiquiátrica, incluindo ansiedade e depressão. CONCLUSÃO: A reatividade do indivíduo ao estresse e os fatores psicossociais desempenham um papel etiológico importante, embora não determinante, podendo interferir no funcionamento intestinal mediante a alteração na motilidade ou espasmo, na diminuição ou aumento de secreção e,finalmente, na irritação. É necessário desenvolver uma metodologia para definir e medir a somatização para o auxílio no diagnóstico clínico e a inclusão dos fatores psicossociais relacionados ao desenvolvimento e persistência dos sintomas nos critérios diagnósticos para a SII.

BACKGROUND: The irritable bowel syndrome (IBS) is a common clinical disorder, however, still poorly understood since the development of symptoms is strongly related to stress, anxiety and depression. OBJECTIVES: To review the literature in order to determine whether, in fact, there is the influence of stress and psychiatric comorbidity in the development, diagnosis and treatment for patients with IBS. METHODS: The review was conducted by searching the database MedLine and Lilacs from 1990 to 2009 using the keywords "stress", "behavior", "psychiatry" and "irritable bowel syndrome". RESULTS: Were selected 38 articles that related irritable bowel syndrome to the individual reaction to stress and psychiatric comorbidity, including anxiety and depression. DISCUSSION: The reactivity of the individual to stress and psychosocial factors play an important etiologic role, although not conclusive, and may interfere with intestinal functioning by altering its motility or spasm, reduction or increase in secretion and, finally, in irritation. It is necessary to develop a methodology for defining and measuring somatization to aid in clinical diagnosis and the inclusion of psychosocial factors related to the development and persistence of symptoms in the diagnostic criteria for IBS.

Síndrome de intestino irritable (SII): nuevos conceptos sobre una antigua enfermedad / Irritable bowel syndrome (IBS): new concepts on an old disease

El síndrome de intestino irritable es un cuadro clínico frecuente caracterizado por malestar/dolor y ditensión abdominal, diarrea, constipación o alternancia de estos síntomas. Tiene un carácter crónico recurrente. El diagnóstico se basa en el cuadro clínico y en la ausencia de síntomas y signos patológicos en los exámenes de rutina. La fisiopatología es compleja y no totalmente esclarecida, reconociéndose la importancia del estrés emocional, las alteraciones de la relación flora intestinal/sistema inmune de la mucosa intestinal y en algunos casos el antecedente de una infección entérica. Es de buen pronóstico y su tratamiento es sintomático. Es importante una óptima relación médico/paciente.

The irritable bowel syndrome is a clinical entity characterized by abdominal distention and pain/discomfort associated with changes in the bowel habit, diarrhoea, constipation or alternating of these symptons. It is a chronic and recurrent condition. Diagnosis is based in the clinical presentation and in the absence of symptoms and signs of severity. The pathophysiology is complex and not completely elucidated although the importance of psychological stress and changes in the relationship of the intestinal flora with the intestinal mucosal immune system are recognized. In some cases a history of intestinal infections is identified. The treatment is addressed to control the symptoms and the prognosis is good. An optimal relationship between the doctor and the patient is of paramount importance.

The Development of Irritable Bowel Syndrome after Shigella Infection: 3 Year Follow-up Study / 대한소화기학회지

BACKGROUND AND AIMS: Bacterial gastroenteritis seems to be a risk factor of irritable bowel syndrome (IBS). The incidence of post-infectious IBS (PI-IBS) was reported to be in the range of 7-31%, but few studies have reported long term follow-up results. So, we investigated the clinical course and prognosis of PI-IBS three years after shigella infection. METHODS: The subjects were recruited from our previous study, in which we investigated the incidence and risk factors of PI-IBS. We had a questionnaire based on interview with 120 controls and 124 patients who had shigella infection three years ago. Both groups were evaluated for the presence of IBS, functional bowel disorders (FBD) except IBS before, one and three years after the infection, respectively. RESULTS: Ninty-five patients (76.6%) and 105 controls (87.5%) completed the questionnare. In patients group, 7 cases had IBS prior to infection (previous IBS), 12 cases (13.8%) had IBS after 1 year (PI-IBS). Four cases developed IBS newly after 3 years (new IBS). Thirteen cases (14.9%) in patients and 4 cases (4.5%) in controls had IBS over 3 years (OR 3.93: 1.20-12.86). The recovery rate over 3 years were 50.0% (2/4) in previous IBS and 25% (3/12) in PI-IBS. The incidence of PI-IBS after 3 years in previous FBD subjects was 28.6% and was 10.6% in normals (p<0.05). The female gender was a risk factor for FBD. CONCLUSIONS: Bacterial gastroenteritis is a trigger factor of IBS. About a quarter of PI-IBS patients are recovered over 3 years. Previous FBD except IBS is a risk factor after 3 years.

Correlation between symptoms of the irritable bowel syndrome and the response to the food extract skin prick test

The relationship between the irritable bowel syndrome (IBS) and food intolerance is not clear. We studied the cutaneous response to food antigens in 43 volunteers who were students and employees of the Faculty of Medicine of Universidade Federal Fluminense. Subjects were divided into 3 groups after evaluation for Roma II criteria for functional disease of the gastrointestinal tract: group I, 14 volunteers with IBS; group II, 15 volunteers with functional dyspepsia; group III, 14 volunteers without habitual gastrointestinal symptoms. The subjects were submitted to the skin prick test with 9 food antigen extracts, for a total of 387 skin tests (9 per volunteer). Of the 126 tests applied to group I, 24 (19.4 percent) were positive (a 3-mm wider papule than the negative control) and of the 135 tests applied to group II, 3 (2.3 percent) were positive. Of the 126 tests applied to group III, 6 (4 percent) were positive. The number of positive responses obtained in group I (IBS) differed significantly from the other 2 groups (P < 0.01). None of the volunteers with IBS reported intolerance to any isolated food. The higher reactivity to food antigens in group I compared to groups II and III suggests that intestinal permeability may be increased in patients with IBS.